Bio Medica Laboratories IPO Allotment Status: Check Latest GMP, Steps to Verify Status
The allotment status for Bio Medica Laboratories’ ₹52.43 crore IPO is expected to be declared today, May 26, 2026. Investors will be able to verify their IPO allotment through the official channels, including the websites of the NSE and that of the IPO registrar, Skyline Financial Services Private Limited.
Procedure to Check IPO Allotment Status Online On NSE
- Visit the NSE’s IPO allotment verification status page here.
- Select “ Equity & SME IPO bid details”.
- In Select Symbol, select “BMLL”
- Enter your PAN No. and Application No.
- Click “Submit”.
Procedure to Check IPO Allotment Status on Skyline Financial Services Private Limited (Registrar to the issue)
- Visit the Skyline Financial Services IPO allotment status page here.
- In Company Name, select “Bio Medica Laboratories”.
- Enter any of the following details.
- DPID/Client ID/ Folio Number
- CAF Number
- PAN Number
- Click “Search”.
Bio Medica Laboratories IPO - Issue Details
Issue Type: Book Building IPO
Total Issue size: ₹52.43 crore
Fresh Issue: ₹47.19 crore
Offer for sale (OFS): ₹5.24 crore
Price Band: ₹132 to ₹139 per share
Lot Size: 1,000 Shares
Book Running Lead Managers: Narnolia Financial Services Limited
Registrar: Skyline Financial Services Private Limited
Listing: NSE SME
Bio Medica Laboratories IPO Overall Subscription Status
[May 25, 2026, 6:50 PM]
|
Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
15.94 |
|
Non-Institutional Investors (NIIs) |
1.30 |
|
Individual Investors |
2.92 |
|
Total |
2.26 |
Bio Medica Laboratories IPO GMP
According to media reports, the Grey Market Premium (GMP) of Bio Medica Laboratories' IPO is ₹0 per share today.
Utilisation of IPO Proceeds
The Company will utilise the net proceeds from the Fresh Issue towards the following purposes:
- Repayment of Loan.
- Enhancement of its existing production capabilities by setting up a new manufacturing facility at the existing premises.
- General Corporate Purposes.
Check out newly listed IPOs on BSE and NSE.
Bio Medica Laboratories Limited Overview
Bio Medica Laboratories Limited specialises in producing Pharmaceutical Parenteral Formulations, with a focus on generic injectables, including Dry Powder and Liquid Injections. Available in single and multi-dose formats, these products serve both veterinary and human medical requirements, addressing a broad spectrum of clinical needs.
The firm employs a B2B contract manufacturing model rather than interacting directly with end users. It develops tailored formulations to meet the unique requirements and technical standards of its clients.
The company reported revenue from operations of ₹3,819.52 crore for FY25, a significant increase from ₹1,524.94 crore in FY24. Total income for FY25 stood at ₹38.32 crore, compared to ₹15.34 crore during the previous fiscal year.
Furthermore, PAT reached ₹9.79 crore in FY25, up from the ₹2.49 crore recorded in FY24.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here